Study of the treatment protocol for blepharitis
Not Applicable
- Conditions
- blepharitis
- Registration Number
- JPRN-UMIN000039106
- Lead Sponsor
- Miyata Eye Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1 Younger than 16 years old. 2 Patients with eyelid diseases (including entropion, eyelid tumor) other than blepharitis. 3 Patients with extraocular inflammatory diseases (including bacterial, fungal, viral, and allergic) other than blepharitis. 4 Patients with severe ocular surface disease. 5 Patients who use of any antibiotic, steroid or immunosuppressant (systemic or topical) within 2 week of enrollment.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Healing rate will be assessed at day 7 and 14.
- Secondary Outcome Measures
Name Time Method Bacteria isolated from lid margin and clinical symptoms and signs at initial visit.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted in blepharitis treatment protocols evaluated in JPRN-UMIN000039106?
How does the observational study JPRN-UMIN000039106 compare novel blepharitis therapies to standard-of-care treatments like azithromycin or corticosteroids?
Which biomarkers correlate with treatment response in meibomian gland dysfunction or anterior blepharitis subtypes within this trial?
What adverse events are reported in blepharitis management strategies involving topical anti-inflammatory agents in Miyata Eye Hospital's study?
Are combination therapies of demulcents and antimicrobial peptides being explored in JPRN-UMIN000039106 for chronic blepharitis treatment optimization?